一个小说,IBS-特定的IgG ELISA-基于消除饮食在刺激性肠综合征:一个随机化,假冒控制的试验
Prashant Singh1, William D Chey1, Will Takakura1
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, Michigan.
Gastroenterology
|February 2, 2025
概括
一种新的免疫球蛋白 (Ig) G抗体引导的消除饮食与虚假饮食相比,显著改善了易怒肠综合征 (IBS) 症状. 这种个性化方法显得有前途,特别是在便秘占主导地位的IBS.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 饮食科学 饮食科学
背景情况:
- 刺激性肠综合征 (IBS) 需要个性化的饮食疗法.
- 基于免疫球蛋白 (Ig) G抗体的消除饮食提供了一个潜在的解决方案.
- 之前对IBS的IgG导向饮食的研究存在方法上的局限性.
研究的目的:
- 为了评估IBS的IgG抗体引导消除饮食的疗效.
- 使用一种新的IBS特异性IgG测定来提供个性化的饮食指导.
- 克服IgG导向饮食干预的先前研究的局限性.
主要方法:
- 一个随机的,双盲的,假的受控试验在8个中心进行.
- 在18种食物IgG试验中,IBS阳性≥1种食物的参与者被随机分类.
- 这项研究比较了为期8周的实验性抗体导向饮食与假饮食.
主要成果:
- 与虚假组相比,实验饮食对象的比例显著增加,达到主要结果 (≥30%的腹痛减少) (59.6%对42.1%,P = .02).
- 亚组分析显示,在便秘占主导地位的IBS和混合肠道习惯的IBS患者中,益处更为强大.
- 实验组在这些特定的IBS亚型中表现出优异的症状改善.
结论:
- 一种IgG导向的消除饮食在改善IBS症状方面比假饮食更有效.
- 基于IgG测试的个性化消除饮食显示了管理IBS的潜力.
- 需要进一步进行更大规模的研究来证实IgG导向的饮食干预措施的这些发现.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
306
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
306
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
118
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
118
Irritable Bowel Syndrome I: Introduction
234
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
234
Drugs for Treatment of Diarrhea-Predominant IBS
142
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
142
Irritable Bowel Syndrome III: Medical and Nursing Management
151
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
151
Inflammatory Bowel Disease IV: Pharmacological Management
100
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
100


